These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 24075706)

  • 1. Physicochemical stability study of a new Trimix formulation for treatment of erectile dysfunction.
    Vieillard V; Eychenne N; Astier A; Yiou R; Deffaux C; Paul M
    Ann Pharm Fr; 2013 Sep; 71(5):358-63. PubMed ID: 24075706
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prostaglandin E1 with phentolamine for the treatment of erectile dysfunction.
    Meinhardt W; de la Fuente RB; Lycklama à Nijeholt AA; Vermeij P; Zwartendijk J
    Int J Impot Res; 1996 Mar; 8(1):5-7. PubMed ID: 8735187
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Evaluation of 452 patients with erectile dysfunction treated by combinations of vasoactive agents by penile injection].
    Segenreich E; Israilov S; Shmueli J; Simon D; Baniel J; Livne P
    Harefuah; 1998 May; 134(9):673-8, 750. PubMed ID: 10909609
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vasoactive cocktails for erectile dysfunction: chemical stability of PGE1, papaverine and phentolamine.
    Soli M; Bertaccini A; Carparelli F; Gotti R; Cavrini V; Andrisano V; Martorana G
    J Urol; 1998 Aug; 160(2):551-5. PubMed ID: 9679927
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term intracavernous therapy responders can potentially switch to sildenafil citrate after radical prostatectomy.
    Raina R; Lakin MM; Agarwal A; Ausmundson S; Montague DK; Zippe CD
    Urology; 2004 Mar; 63(3):532-7; discussion 538. PubMed ID: 15028452
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Response to intracavernous administration of 3 different drugs in the same group of patients with erectile dysfunction].
    Ribé N; Rajmil O; Bassas L; Jurado C; Pomerol JM
    Arch Esp Urol; 2001 May; 54(4):355-9. PubMed ID: 11455770
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intracavernous injections for erectile dysfunction in patients with cardiovascular diseases and failure or contraindications for sildenafil citrate.
    Israilov S; Niv E; Livne PM; Shmueli J; Engelstein D; Segenreich E; Baniel J
    Int J Impot Res; 2002 Feb; 14(1):38-43. PubMed ID: 11896476
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Prostaglandin E1 in erectile dysfunction].
    Porst H
    Urologe A; 1989 Mar; 28(2):94-8. PubMed ID: 2655258
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Physicochemical stability of papaverine hydrochloride-phentolamine mesylate mixtures used for intracavernous injection: a preliminary evaluation.
    Hadzija BW; Mattocks AM; Stahl GM
    J Urol; 1988 Jul; 140(1):64-5. PubMed ID: 2454330
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Intracavernous injection of vasoactive drugs for treating erectile impotence].
    Yasumoto R; Asakawa M; Kawashima H; Yoshimura R; Maekawa T; Kashiwara N; Tanaka H; Nishio S
    Hinyokika Kiyo; 1988 Feb; 34(2):301-4. PubMed ID: 2454019
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Prospective study of the effectiveness and side effects of intracavernous prostaglandin E1 versus papaverine or papaverine phentolamine in the diagnosis and treatment of erection dysfunction. Review of the literature].
    Chandeck Montesa K; Chen Jiménez J; Tamayo JC; Rodríguez Antolín A; Alvarez González E
    Actas Urol Esp; 1992 Mar; 16(3):208-16. PubMed ID: 1621545
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prostaglandin E1 versus mixture of prostaglandin E1, papaverine and phentolamine in nonresponders to high papaverine plus phentolamine doses.
    Bechara A; Casabé A; Chéliz G; Romano S; Fredotovich N
    J Urol; 1996 Mar; 155(3):913-4. PubMed ID: 8583605
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Value of prostaglandin El in the diagnosis of erectile dysfunction in comparison with papaverine and papaverine/phentolamine in 61 patients with erectile dysfunction].
    Porst H
    Urologe A; 1988 Jan; 27(1):22-6. PubMed ID: 3284144
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Endocavernous drug infusions revisited].
    Bellorofonte C; Ruoppolo M; Dell'Acqua S; Zaatar C; Ferri PM; Yamak R; Tagliaferri A; Tombolini P
    Arch Ital Urol Nefrol Androl; 1991 Dec; 63(4):475-9. PubMed ID: 1838835
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The rationale for prostaglandin E1 in erectile failure: a survey of worldwide experience.
    Porst H
    J Urol; 1996 Mar; 155(3):802-15. PubMed ID: 8583582
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Current role of intracavernous therapy in the treatment of erectile dysfunction].
    Asuar Aydillo S
    Arch Esp Urol; 2002 Jun; 55(5):475-82. PubMed ID: 12174413
    [No Abstract]   [Full Text] [Related]  

  • 17. [Pharmacotherapy of erectile dysfunction].
    Shcheplev PA; Nesterov SN; Kukharkin SA; Abdullaev IA; Sidorov DV
    Ter Arkh; 1999; 71(10):76-8. PubMed ID: 10612182
    [No Abstract]   [Full Text] [Related]  

  • 18. Stability evaluation of a prostaglandin E1 saline solution packed in insulin syringes.
    Uebel RA; Wium CA; Schmidt AC
    Int J Impot Res; 2001 Feb; 13(1):16-7. PubMed ID: 11313835
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Determinants of satisfactory rigidity after intracavernosal injection with prostaglandin E1 in men with erectile failure.
    Purvis K; Brekke I; Christiansen E
    Int J Impot Res; 1996 Mar; 8(1):9-16. PubMed ID: 8735188
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Prostaglandin E1 injection in erectile dysfunction. Current diagnostic and therapeutic possibilities].
    Schrey A
    Fortschr Med; 1990 Oct; 108(30):577-80. PubMed ID: 2245960
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.